SUPPLEMENTARY TABLE S3. Serious adverse events (AEs) and/or AEs leading to withdrawal from study

|  |  |  |
| --- | --- | --- |
|  | Mesalamine dose groups | |
|  | Low dose | High dose |
| Serious AEs |  |  |
| Exacerbation of ulcerative colitis | 1 | 1 |
| Adenovirus infection | 1 |  |
| Sclerosing cholangitis | 1 |  |
| Pancreatitis | 1 |  |
| Sinusitis | 1 |  |
| Abdominal pain | 1 |  |
| Decreased body mass index | 1 |  |
| Hemorrhagic diarrhea | 1 |  |
| Anemia |  | 1 |
| Syncope |  | 1 |
| AEs leading to withdrawal |  |  |
| Ulcerative colitis flare | 3 |  |
| Adenovirus infection | 1 |  |
| Sclerosing cholangitis | 1 |  |
| Pancreatitis | 1 |  |
| Serum elevated amylase level |  | 1 |
| Increased lipase |  | 1 |
| Upper abdominal pain |  | 1 |